Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Enobosarm

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Veru to Present at the 2024 Cantor Global Healthcare Conference
    Veru to Present at the 2024 Cantor Global Healthcare Conference

    11 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/11/2944465/11676/en/Veru-to-Present-at-the-2024-Cantor-Global-Healthcare-Conference.html

    GLOBENEWSWIRE
    11 Sep 2024
    Share Share
    Veru Names Steven Heymsfield Principal Investigator For Enobosarm Trial
    Veru Names Steven Heymsfield Principal Investigator For Enobosarm Trial

    15 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/15/2882418/11676/en/Veru-Announces-Steven-B-Heymsfield-M-D-as-the-Principal-Investigator-for-its-Enobosarm-Phase-2b-Clinical-Trial-for-High-Quality-Weight-Loss.html

    GLOBENEWSWIRE
    15 May 2024
    Share Share
    Veru Fiscal Q2 2024 Results, Enobosarm Weight Loss Program
    Veru Fiscal Q2 2024 Results, Enobosarm Weight Loss Program

    08 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/08/2877612/11676/en/Veru-Reports-Fiscal-2024-Second-Quarter-Financial-Results-and-Progress-of-its-Enobosarm-High-Quality-Weight-Loss-Clinical-Program.html

    GLOBENEWSWIRE
    08 May 2024
    Share Share
    Veru Announces Date of 2024 Annual Meeting of Shareholders
    Veru Announces Date of 2024 Annual Meeting of Shareholders

    01 Apr 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/04/01/2855433/11676/en/Veru-Announces-Date-of-2024-Annual-Meeting-of-Shareholders.html

    GLOBENEWSWIRE
    01 Apr 2024
    Share Share
    Veru Announces FDA Clearance of IND Application to Initiate Ph 2b with Enobosarm
    Veru Announces FDA Clearance of IND Application to Initiate Ph 2b with Enobosarm

    06 Feb 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/02/06/2824317/11676/en/Veru-Announces-FDA-Clearance-of-IND-Application-to-Initiate-Phase-2b-Clinical-Trial-with-Enobosarm-to-Treat-Muscle-Loss-Associated-with-Weight-Loss-Drugs.html

    GLOBENEWSWIRE
    06 Feb 2024
    Share Share
    Veru Submits IND Application to FDA for the Development of Enobosarm
    Veru Submits IND Application to FDA for the Development of Enobosarm

    08 Jan 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/01/08/2805447/11676/en/Veru-Submits-IND-Application-to-FDA-for-the-Development-of-Enobosarm-to-Prevent-Muscle-Loss-While-Augmenting-Fat-Loss-in-Combination-with-GLP-1-Drugs-for-Weight-Loss.html

    GLOBENEWSWIRE
    08 Jan 2024
    Share Share